Abstract
Purpose
This study evaluated the efficacy and safety of everolimus (EVE) plus exemestane (EXE) in hormone-receptor positive (HR+), human epidermal growth factor receptor-2-negative (HER2−) metastatic breast cancer (MBC) patients in real-life settings.
Methods
Overall, 204 HR+, HER2− MBC patients treated with EVE + EXE after progressing following prior endocrine treatment were included. Overall survival (OS) and progression-free survival (PFS) and safety data were analyzed.
Results
The objective response rate, median PFS, and median OS were 33.4%, 8.9 months, and 23.4 months, respectively. Multivariate analysis revealed that negative progesterone receptor status was a significant determinant of poor treatment response (p = 0.035) and PFS (p = 0.024). The presence of bone-only metastasis was associated with better treatment response (p = 0.002), PFS (p < 0.001), and OS (p = 0.001).
Conclusion
We confirmed the favorable efficacy and safety profile of EVE + EXE for HR+, HER − MBC patients.
Acknowledgments
This study was presented in SABCS, 2018, San Antonio Breast Cancer Symposium, in a poster session. A. Bilici, S. Menekse, S. Akın, M. Degirmenci, O. F. Olmez, N. Avci, T. Sakalar, D. Tural, M. A. Kaplan, O. Tanriverdi, I. Bilgetekin, and R. Uslu. The efficacy and safety analysis of the treatments of EVE and EXE combination in 101 metastatic breast cancer patients: real-life experience from Turkey. P6-18-37.
Author contributions
A. B., M. U., and S. M. were involved in the conception and design of the study. All authors were involved in acquisition, analysis and interpretation of data. All authors were involved in the writing, review, and/or revision of this manuscript. All authors have read and approved the final manuscript.
Disclosure statement
The authors report no conflicts of interest. The authors alone are responsible for the content and writing of the article.